Professor IAN SAYERS ian.sayers@nottingham.ac.uk
Professor of Respiratory Molecular Genetics
Interleukin‐1 receptor‐associated kinase 4 (IRAK4) is a critical regulator of inflammatory signalling through toll‐like receptors 4 and 7/8 in murine and human lungs
Sayers, Ian; Thakker, Dhruma; Billington, Charlotte; Kreideweiss, Stefan; Grundl, Marc A.; Bouyssou, Thierry; Thamm, Sven; Kreuz, Sebastian; Hall, Ian P.
Authors
Dhruma Thakker
Charlotte Billington
Stefan Kreideweiss
Marc A. Grundl
Thierry Bouyssou
Sven Thamm
Sebastian Kreuz
IAN HALL IAN.HALL@NOTTINGHAM.AC.UK
Professor of Molecular Medicine
Abstract
Background and Purpose: Toll‐like receptors 4 (TLR4) and TLR7/TLR8 play an important role in mediating the inflammatory effects of bacterial and viral pathogens. Interleukin‐1 receptor‐associated kinase 4 (IRAK4) is an important regulator of signalling by toll‐like receptor (TLR) and hence is a potential therapeutic target in diseases characterized by increased lung inflammatory signalling. Experimental Approach: We used an established murine model of acute lung inflammation, and studied human lung tissue ex vivo, to investigate the effects of inhibiting IRAK4 on lung inflammatory pathways. Key Results: We show that TLR4 stimulation produces an inflammatory response characterized by neutrophil influx and tumour necrosis factor‐α (TNF‐α) production in murine lungs and that these responses are markedly reduced in IRAK4 kinase‐dead mice. In addition, we characterize a novel selective IRAK4 inhibitor, BI1543673, and show that this compound can reduce lipopolysaccharide (LPS)‐induced airway inflammation in wild‐type mice. Additionally, BI1543673 reduced inflammatory responses to both TLR4 and TLR7/8 stimulation in human lung tissue studied ex vivo. Conclusion and Implications: These data demonstrate a key role for IRAK4 signalling in lung inflammation and suggest that IRAK4 inhibition has potential utility to treat lung diseases characterized by inflammatory responses driven through TLR4 and TLR7/8.
Citation
Sayers, I., Thakker, D., Billington, C., Kreideweiss, S., Grundl, M. A., Bouyssou, T., Thamm, S., Kreuz, S., & Hall, I. P. (2024). Interleukin‐1 receptor‐associated kinase 4 (IRAK4) is a critical regulator of inflammatory signalling through toll‐like receptors 4 and 7/8 in murine and human lungs. British Journal of Pharmacology, https://doi.org/10.1111/bph.16509
Journal Article Type | Article |
---|---|
Acceptance Date | May 23, 2024 |
Online Publication Date | Aug 13, 2024 |
Publication Date | Aug 13, 2024 |
Deposit Date | Sep 23, 2024 |
Publicly Available Date | Sep 27, 2024 |
Journal | British Journal of Pharmacology |
Print ISSN | 0007-1188 |
Electronic ISSN | 1476-5381 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
DOI | https://doi.org/10.1111/bph.16509 |
Keywords | exacerbations, lung inflammation, toll‐ like receptors, interstitial lung disease, chronic obstructive pulmonary disease, IRAK4 |
Public URL | https://nottingham-repository.worktribe.com/output/38630204 |
Publisher URL | https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.16509 |
Files
British J Pharmacology - 2024 - Sayers - Interleukin‐1 receptor‐associated kinase 4 IRAK4 is a critical regulator of
(1.7 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Genome-wide association study to identify genetic determinants of severe asthma
(2012)
Journal Article
Leukotriene B4 receptor locus gene characterisation and association studies in asthma
(2012)
Journal Article
GSTCD and INTS12 regulation and expression in the human lung
(2013)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search